Adverse events related to treatment · non‐ambulatory children with SMA types II and III
Oral valproic acid plus acetyl‐L‐carnitine showed no clear difference in adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events related to treatment · children with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · ambulatory adults with SMA type III
Oral valproic acid showed no clear difference in adverse events related to treatment compared with placebo (low certainty).
1 finding from 1 review
RR 0.8 [0.44, 1.44]
33 participants
Low
Number of women with adverse events · women with breast engorgement during lactation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · women with breast engorgement during lactation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · women with breast engorgement during lactation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · women with breast engorgement during lactation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · postpartum breastfeeding women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of women with adverse events · postpartum breastfeeding women
Probiotics may leads to lower number of women with adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events ‐ Multiple pregnancy · women with subfertility
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).
1 finding from 1 review
Adverse events per woman · Subfertile women undergoing assisted reproduction
1 finding from 1 review
Adverse events: renal insufficiency · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in adverse events: renal insufficiency compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether IV changes adverse events: bacterial infection compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Adverse events: somnolence/sedation · acute mania
Lithium showed no clear difference in adverse events: somnolence/sedation compared with aripiprazole (moderate certainty).
1 finding from 1 review